Beckley builds case for its psychedelic depression therapy

Beckley Psytech, just months away from a readout of a phase 2b trial of its psychedelic therapy for treatment-resistant depression (TRD), has built anticipation with new data showing a rapid and durable effect in an earlier-stage trial.